Will the $66 billion buyout of Allergan by Actavis suck some of the juice out of Orange County, Calif., which Allergan's called home for 60 years?
Pioneering live interview series from MassDevice.com will close its 2014 season this week in Irvine, Calif. with Masimo CEO Joe Kiani and Caroll Neubauer, CEO, B. Braun Medical.
DeviceTalks, the live interview series featuring thought leaders from the $126B medical technology industry, closes out its 2014 season on November 19, 2014 in Irvine, Calif. with a conversation focused on whether the medical device industry is doing enough to protect patients.
In this DeviceTalks preview, we catch up with Masimo CEO Joe Kiani to discuss new challenges facing the company and how medtech can break the cycle of the era of 'good-enough' innovation.
Masimo Corporation’s chief executive is a leading voice in the movement to reduce medical errors, but the Food and Drug Administration says his company isn’t properly investigating complaints.
(Courtesy of the Patient Safety Movement Foundation)
by Marshall Allen and Annie Waldman, ProPublica
This story was co-published with NPR's Shots blog.
Here's a look at some of the top legal news stories for medical device companies this week: Appeals court vacates FDA's rescission of ReGen's MenaFlex implant; Masimo wins $467m verdict in patent spat with Philips; Endo reaches deal to end remaining U.S. lawsuits over mesh; Judge halves $74m pelvic mesh verdict against Boston Scientific; Judge tosses FDA whistleblowers lawsuit
A jury delivers a $467 million verdict for Masimo in a patent infringement spat with Royal Philips over pulse oximetry technology.
Masimo wins clearance in Japan and approval in Europe for its rainbow DCI-mini non-invasive hemoglobin monitor for infants and small kids.
California-based medical device maker Masimo (NSDQ:MASI) is planning a limited market launch of its 1st-of-its kind hemoglobin monitor for infants and small children after winning approval from regulators in Japan and Europe.